Research indicates upregulated FBXO2 expression in liver tissue from NAFLD patients, with FBXO2 overexpression linked to lipid accumulation in HepG2 cells (Liu et al. 2023). Here, FBXO2 is linked to metabolic dysfunction-associated steatotic liver disease.